• Return to search results
• Start new search

Investigator(s):
Wyndham H. Wilson, M.D., Ph.D. Principal Investigator Phone: 301-435-2415 wilsonw@mail.nih.gov
Referral Contact(s):
Peggy Shovlin, R.N., B.S.N. Research Nurse Phone: 301-594-6597 mshovlin@mail.nih.gov

---

Key Eligibility Criteria:

• Diagnosis of Grade I, II, III LYG
• Prior chemotherapy allowed
• Age 12 and older

---

Study Outline:

• Patients with grade I and II LYG receive interferon α 3 times per week for 1 year beyond best response
• Patients with grade III LYG or progressive grade I/II on interferon α receive dose-adjusted EPOCH-R chemotherapy
• Patients that progress or develop large cell NHL receive dose-adjusted EPOCH-R chemotherapy

---

Additional Information:

• This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
• There is no charge for medical care received at NIH Clinical Center.
• FAQs about this study - provides information for patients about the trial such as frequency and duration of visits, costs, how to enroll, and study outline.
• PDQ (Physicians Data Query) - provides additional details about this study for health care providers.

Reviewed: 9/6/12
Updated: 2/7/12